Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
CN Stock MarketDetailed Quotes
600812 North China Pharmaceutical
- 6.08
- +0.13+2.18%
Market Closed May 16 15:00 CST
10.43BMarket Cap62.68P/E (TTM)
6.09High5.95Low266.46KlotVolume5.97Open5.95Pre Close160.95MTurnover1.55%Turnover Ratio82.16P/E (Static)1.72BShares6.9152wk High1.91P/B10.43BFloat Cap4.0252wk Low6.55Limit Up1.72BShs Float20.14Historical High5.36Limit Down2.35%Amplitude0.62Historical Low0.01Dividend TTM6.04Avg Price102.07KlotAsk0.16%Div YieldTTM100Lot Size160.83KlotBid
North China Pharmaceutical Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 0.65%2.57B | -2.48%9.87B | -5.20%7.56B | -0.04%5.23B | -3.86%2.56B | -3.62%10.12B | 1.29%7.97B | -0.86%5.23B | 4.59%2.66B | 1.11%10.5B |
| Operating revenue | 0.65%2.57B | -2.48%9.87B | -5.20%7.56B | -0.04%5.23B | -3.86%2.56B | -3.62%10.12B | 1.29%7.97B | -0.86%5.23B | 4.59%2.66B | 1.11%10.5B |
| Other operating revenue | ---- | 42.61%71.76M | ---- | 17.46%27.14M | ---- | -1.70%50.32M | ---- | -3.08%23.11M | ---- | -36.17%51.19M |
| Total operating cost | -0.93%2.47B | -4.39%9.6B | -5.90%7.4B | -0.85%5.11B | -5.03%2.49B | -2.61%10.04B | 1.50%7.86B | -0.19%5.16B | 5.05%2.62B | -0.44%10.31B |
| Operating cost | 2.32%1.82B | -2.45%6.71B | -3.16%5.27B | 4.23%3.67B | 0.20%1.78B | -1.59%6.88B | 3.25%5.44B | -0.67%3.52B | 4.63%1.77B | 4.36%7B |
| Operating tax surcharges | 7.09%26.8M | 4.84%109.28M | -1.73%77.37M | -15.53%51.94M | -17.31%25.02M | -11.34%104.23M | -8.79%78.73M | 11.35%61.5M | 3.36%30.26M | -4.67%117.57M |
| Operating expense | -12.34%321.96M | -13.41%1.43B | -21.66%1.05B | -16.82%744.35M | -20.70%367.27M | -10.24%1.66B | -0.30%1.34B | 6.51%894.9M | 7.24%463.12M | -14.68%1.84B |
| Administration expense | 0.10%134.05M | -7.67%581.89M | -4.69%415.24M | -11.12%270.49M | -16.93%133.92M | 7.47%630.24M | -11.54%435.7M | -10.25%304.31M | -3.96%161.22M | -8.53%586.41M |
| Financial expense | -22.45%89.12M | -9.94%425.77M | -7.23%326.81M | -7.22%220.46M | -12.77%114.91M | -14.29%472.75M | -13.81%352.29M | -17.38%237.61M | -7.64%131.73M | -4.32%551.57M |
| -Interest expense (Financial expense) | -19.20%97.4M | -8.61%458.7M | -8.90%345.92M | -8.34%238.7M | -6.95%120.54M | -16.27%501.9M | -17.95%379.71M | -17.22%260.43M | -16.39%129.55M | -6.74%599.39M |
| -Interest Income (Financial expense) | -2.76%-6.55M | 8.71%-25.26M | 14.53%-18.45M | 16.07%-12.11M | -23.33%-6.38M | 31.09%-27.67M | 35.99%-21.59M | 46.22%-14.43M | 70.18%-5.17M | 54.12%-40.15M |
| Research and development | 6.23%80.97M | 13.48%337.28M | 22.56%251.67M | 13.12%160.55M | 14.59%76.22M | 36.77%297.2M | 50.98%205.36M | 35.94%141.93M | 99.52%66.51M | 41.94%217.3M |
| Credit Impairment Loss | -13.62%-21.59M | -3,283.66%-22.68M | 83.30%-6.42M | 6.58%-19.39M | -56.99%-19.01M | 99.91%-670.16K | -33.70%-38.43M | 31.35%-20.75M | 27.07%-12.11M | -4,161.29%-772.94M |
| Asset Impairment Loss | 287.61%6.61M | -13.12%-16.37M | 136.99%8.35M | 170.65%10.53M | 60.80%-3.53M | 78.05%-14.48M | 18.77%-22.58M | 23.43%-14.91M | -19,853.75%-8.99M | -605.21%-65.93M |
| Other net revenue | 71.30%-2.11M | -44.32%44.27M | 930.37%58.45M | 305.78%31.37M | -960.26%-7.36M | 110.52%79.5M | 120.30%5.67M | 156.53%7.73M | 121.71%855.91K | -790.81%-755.64M |
| Invest income | -1.50%7.6M | -1.47%46.16M | -2.18%33.42M | -6.23%22.29M | -21.34%7.71M | 6.43%46.85M | 28.77%34.16M | 31.58%23.77M | 4.03%9.81M | 12.54%44.02M |
| -Including: Investment income associates | -1.40%7.4M | 7.64%44.92M | 10.73%32.48M | 8.67%21.58M | -23.43%7.51M | -1.64%41.73M | 10.58%29.34M | 9.94%19.86M | 4.03%9.81M | 13.35%42.43M |
| Asset deal income | --4.25K | -41.24%444.16K | -32.47%440.88K | -5.97%438.81K | ---- | 70.54%755.82K | 215.52%652.82K | 179.98%466.65K | 167.03%362.68K | -85.30%443.19K |
| Other revenue | -29.37%5.27M | -21.96%36.71M | -28.89%22.66M | -8.64%17.5M | -36.75%7.46M | 21.32%47.04M | -3.87%31.86M | 3.32%19.16M | 216.23%11.79M | -46.41%38.77M |
| Operating profit | 78.43%102.92M | 99.22%311.68M | 84.39%223.1M | 78.85%147.59M | 58.24%57.68M | 127.56%156.45M | -8.66%120.99M | -14.56%82.52M | -11.49%36.45M | -517.28%-567.63M |
| Add:Non operating Income | -31.31%375.65K | -32.07%6.94M | -53.29%3.34M | -45.03%3M | -77.90%546.86K | 147.64%10.21M | 123.88%7.15M | 182.02%5.46M | 137.87%2.47M | -41.42%4.12M |
| Less:Non operating expense | -30.83%138.83K | 8.06%8.79M | 227.38%3.46M | -14.69%579.11K | 53.73%200.71K | 419.60%8.13M | -23.66%1.06M | -47.02%678.79K | 219.47%130.55K | -80.84%1.56M |
| Total profit | 77.77%103.15M | 95.43%309.83M | 75.46%222.98M | 71.83%150.01M | 49.57%58.02M | 128.06%158.54M | -5.35%127.08M | -10.22%87.3M | -8.03%38.8M | -518.87%-565.07M |
| Less:Income tax cost | 5.14%26.53M | -13.08%94.87M | -0.22%76.54M | 18.02%52.51M | -21.76%25.23M | -4.01%109.15M | -3.56%76.7M | -17.25%44.49M | 40.29%32.25M | 14.25%113.71M |
| Net profit | 133.66%76.63M | 335.26%214.97M | 190.66%146.44M | 127.77%97.5M | 400.97%32.79M | 107.28%49.39M | -7.95%50.38M | -1.52%42.8M | -65.90%6.55M | -2,018.43%-678.78M |
| Net profit from continuing operation | 133.66%76.63M | 335.26%214.97M | 190.66%146.44M | 127.77%97.5M | 400.97%32.79M | 107.28%49.39M | -7.95%50.38M | -1.52%42.8M | -65.90%6.55M | -2,018.43%-678.78M |
| Less:Minority Profit | 30.68%19.13M | 97.71%87.97M | 96.24%43.98M | 56.91%25.51M | 1,200.57%14.64M | 325.82%44.5M | 33.39%22.41M | 46.63%16.26M | -79.59%1.13M | -37.26%10.45M |
| Net profit of parent company owners | 216.72%57.49M | 2,496.80%126.99M | 266.29%102.46M | 171.17%71.98M | 234.89%18.15M | 100.71%4.89M | -26.26%27.97M | -18.01%26.55M | -60.38%5.42M | -3,780.33%-689.23M |
| Earning per share | ||||||||||
| Basic earning per share | 209.09%0.034 | 2,366.67%0.074 | 275.00%0.06 | 180.00%0.042 | 266.67%0.011 | 100.75%0.003 | -27.27%0.016 | -21.05%0.015 | -62.50%0.003 | -3,754.55%-0.402 |
| Diluted earning per share | 209.09%0.034 | 2,366.67%0.074 | 275.00%0.06 | 180.00%0.042 | 266.67%0.011 | 100.75%0.003 | -27.27%0.016 | -21.05%0.015 | -62.50%0.003 | -3,754.55%-0.402 |
| Other composite income | 3.27%39.72K | 179.88%1.6M | -109.33%-150.2K | -53.29%792.34K | 103.11%38.46K | -133.95%-2M | -79.08%1.61M | -43.24%1.7M | -235.46%-1.24M | 308.17%5.91M |
| Other composite income of parent company owners | 3.27%39.72K | 179.88%1.6M | -109.33%-150.2K | -53.29%792.34K | 103.11%38.46K | -133.95%-2M | -79.08%1.61M | -43.24%1.7M | -235.46%-1.24M | 308.17%5.91M |
| Total composite income | 133.50%76.67M | 357.06%216.57M | 181.37%146.29M | 120.87%98.29M | 518.45%32.83M | 107.04%47.38M | -16.72%51.99M | -4.20%44.5M | -71.80%5.31M | -2,167.51%-672.88M |
| Total composite income of parent company owners | 216.26%57.53M | 4,356.75%128.59M | 245.86%102.31M | 157.69%72.78M | 334.87%18.19M | 100.42%2.89M | -35.17%29.58M | -20.14%28.24M | -68.58%4.18M | -4,400.20%-683.33M |
| Total composite income of minority owners | 30.68%19.13M | 97.71%87.97M | 96.24%43.98M | 56.91%25.51M | 1,200.57%14.64M | 325.82%44.5M | 33.39%22.41M | 46.63%16.26M | -79.59%1.13M | -37.26%10.45M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Lianda Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongtianyun Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Zhongtianyun Certified Public Accountants Co., Ltd. (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting